What question did this study set out to answer?

To assess the efficacy of abemaciclib combined with endocrine therapy in preventing early recurrence in high-risk HR+, HER2- early breast cancer.

September 20, 2020Journal of Clinical OncologyOpen Access

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

View Full Paper

Ask AI

Bookmark

To assess the efficacy of abemaciclib combined with endocrine therapy in preventing early recurrence in high-risk HR+, HER2- early breast cancer.
Open-label, phase III study with patients randomly assigned (1:1) to endocrine therapy alone or with abemaciclib (150 mg twice daily for 2 years).
Inclusion criteria included HR+, HER2-, high-risk early breast cancer patients with specific node and tumor characteristics.
Primary endpoint was invasive disease-free survival, with secondary endpoints including distant relapse-free survival and overall survival.
Abemaciclib improved invasive disease-free survival (IDFS) with a hazard ratio of 0.75 (95% CI, 0.60 to 0.93), P=0.01.
The 2-year IDFS rates were 92.2% for the abemaciclib group versus 88.7% for the control group.
Safety profile remained consistent with known effects of abemaciclib.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows improved invasive disease-free survival in high-risk early breast cancer patients with adjuvant therapy, indicating a promising treatment option.

Cite This Study

Johnston et al. (2020) studied this question.

synapsesocial.com/papers/6a6368bb1ec0c1a689b6fb77 https://doi.org/10.1200/jco.20.02514

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows improved invasive disease-free survival in high-risk early breast cancer patients with adjuvant therapy, indicating a promising treatment option.

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Key Points

Discussion

Implication

Cite This Study

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading